<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857359</url>
  </required_header>
  <id_info>
    <org_study_id>ADX48621-301</org_study_id>
    <nct_id>NCT04857359</nct_id>
  </id_info>
  <brief_title>Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy</brief_title>
  <official_title>Phase 2b/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients With Parkinson's Disease Receiving Levodopa-based Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Addex Pharma S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Addex Pharma S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients&#xD;
      with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg&#xD;
      per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the&#xD;
      Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment&#xD;
      period may have the option to roll into an open-label safety extension study for an&#xD;
      additional 12-month treatment period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline on the Unified Dyskinesia Rating Scale (UDysRS) total score</measure>
    <time_frame>Baseline (Day 1) to Week 12</time_frame>
    <description>The UDysRS is a dyskinesia rating scale scored from 0-104 that evaluates involuntary movements associated with PD. A higher score indicates more severe dyskinesia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ON time without troublesome dyskinesia based on a standardized PD diary</measure>
    <time_frame>Baseline (Day 1) to Week 12</time_frame>
    <description>A PD home diary is used to score 5 different conditions in 30-minute time intervals: ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in OFF time based on a standardized PD diary</measure>
    <time_frame>Baseline (Day 1) to Week 12</time_frame>
    <description>A PD home diary is used to score 5 different conditions in 30-minute time intervals: ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Dyskinesia, Drug-Induced</condition>
  <condition>Dyskinesias</condition>
  <arm_group>
    <arm_group_label>Dipraglurant TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo TID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipraglurant</intervention_name>
    <description>Oral 50mg and 100mg tablet</description>
    <arm_group_label>Dipraglurant TID</arm_group_label>
    <other_name>ADX48621</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral matching placebo tablet</description>
    <arm_group_label>Placebo TID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with Parkinson's Disease on a stable regimen of antiparkinson's medications,&#xD;
             including a levodopa preparation administered not less than 3 times daily.&#xD;
&#xD;
          -  Meet protocol-specified criteria for moderate to severe dyskinesia symptoms based on&#xD;
             UDysRS and Movement Disorder Society - Unified Parkinson's Disease Rating Scale&#xD;
             (MDS-UPDRS) assessments.&#xD;
&#xD;
          -  Meet protocol specified criteria for ON time with troublesome dyskinesia based on a&#xD;
             standard PD home diary.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior surgical treatment for Parkinson's Disease (e.g., deep brain stimulation).&#xD;
&#xD;
          -  Other neurological disease (including psychiatric disease and/or cognitive impairment)&#xD;
             that, in the opinion of the investigator, would affect the patient's ability to&#xD;
             complete study assessments.&#xD;
&#xD;
          -  Other significant medical condition that may affect the safety of the patient or&#xD;
             preclude adequate participation in the study.&#xD;
&#xD;
          -  Pregnant or breast-feeding. Female patients who are of child-bearing potential must be&#xD;
             using adequate contraceptive methods (e.g. oral contraceptive, double-barrier method,&#xD;
             intra-uterine device, intra-muscular hormonal contraceptive), and have a negative&#xD;
             pregnancy test at Screening.&#xD;
&#xD;
        Other protocol-defined inclusion and exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>877-409-1775</phone>
    <email>Clinical.Team@addexpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xenosciences Inc</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Flitman</last_name>
      <phone>602-265-6500</phone>
      <email>sflitman@xenoscience.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neuro-Pain Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perminder Bhatia</last_name>
      <phone>559-437-9700</phone>
      <email>bhatia@neuropain.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Medical Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Morenkova</last_name>
      <phone>949-824-0351</phone>
      <email>amorenko@hs.uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Movement Disorders Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajeev Kumar</last_name>
      <phone>303-357-5445</phone>
      <email>rajeev_kumar@msn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chase Family Movement Disorders Center - Vernon</name>
      <address>
        <city>Vernon</city>
        <state>Connecticut</state>
        <zip>06066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Antonelle de Marcaida</last_name>
      <phone>860-870-6385</phone>
      <email>joyantonelle.demarcaida@hhchealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders Center of Boca Raton Inc</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart Isaacson</last_name>
      <phone>561-392-1818</phone>
      <email>isaacson_research@parkinsonscenter.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research -21 NE 1st Ave</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anette Nieves</last_name>
      <phone>352-629-5800</phone>
      <email>anette.nieves@renstar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AES - DRS - Synexus Clinical Research US, Inc. - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ira Goodman</last_name>
      <phone>407-426-9299</phone>
      <email>ira.goodman@globalaes.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurology Associates of Ormond Beach</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David McDonald</last_name>
      <phone>386-676-6340</phone>
      <email>neurodmcdonald@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suncoast Neuroscience Associates Inc</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Vasquez</last_name>
      <phone>727-202-2623</phone>
      <email>abvmd@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-4799</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Zesiewicz</last_name>
      <phone>813-974-5909</phone>
      <email>tzesiewi@hsc.usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Geodyssey Research LLC</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart Shafer</last_name>
      <phone>772-492-7051</phone>
      <phone_ext>228</phone_ext>
      <email>stjashafer@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Morgan</last_name>
      <phone>706-721-2798</phone>
      <email>jmorgan@augusta.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NeuroStudies.net, LLC - ClinEdge - PPDS</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marshall Nash</last_name>
      <phone>404-475-0552</phone>
      <email>mnash@accelclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard Verhagen Metman</last_name>
      <phone>312-563-2900</phone>
      <email>Leonard_A_Verhagen@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmad El Kouzi</last_name>
      <phone>217-545-8000</phone>
      <email>aelkouzi84@siumed.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Josephson Wallack Munshower Neurology PC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi George</last_name>
      <phone>317-537-6060</phone>
      <email>kristikgeorge@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajesh Pahwa</last_name>
      <phone>913-588-7159</phone>
      <email>rpahwa@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <zip>48025-4334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter LeWitt</last_name>
      <phone>248-325-2452</phone>
      <email>plewitt1@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Goudreau</last_name>
      <phone>517-353-8122</phone>
      <email>goudrea2@msu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers, the State University of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Chen</last_name>
      <phone>732-235-7729</phone>
      <email>jc2478@rwjms.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Health Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106-2719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Pirio Richardson</last_name>
      <phone>505-272-2515</phone>
      <email>spiriorichardson@salud.unm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>David L Kreitzman MD PC</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Kreitzman</last_name>
      <phone>631-462-7774</phone>
      <email>pdmdcli@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winona Tse</last_name>
      <phone>212-241-5607</phone>
      <email>winona.tse@mssm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Gostkowski</last_name>
      <phone>216-444-9715</phone>
      <email>gostkom@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariane Park</last_name>
      <phone>614-293-4969</phone>
      <email>park.485@osu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Toledo, Gardner-McMaster Parkinson Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Elmer</last_name>
      <phone>419-383-6728</phone>
      <email>lawrence.elmer@utoledo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abington Neurologic Associates</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001-3816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Weisman</last_name>
      <phone>215-957-9250</phone>
      <phone_ext>3279</phone_ext>
      <email>dcweisman@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Deik</last_name>
      <phone>215-829-7273</phone>
      <email>Andres.deik@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Davis</last_name>
      <phone>615-936-2025</phone>
      <email>thomas.l.davis@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Health Science Center, San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Horn</last_name>
      <phone>210-450-0500</phone>
      <email>horns@uthscsa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research (Norfolk, Virginia)</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502-3932</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Fuentes</last_name>
      <phone>757-226-0655</phone>
      <email>cfuentes@mcrmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sentara Neurology Specialists</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Thomas</last_name>
      <phone>757-507-0600</phone>
      <email>kmthoma3@sentara.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evergreen Hospital Medical Center</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pinky Agarwal</last_name>
      <phone>425-899-5385</phone>
      <email>pagarwal@evergreenhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Froedtert and The Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-0509</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Blindauer</last_name>
      <phone>414-805-5223</phone>
      <email>kblindauer@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>October 3, 2021</last_update_submitted>
  <last_update_submitted_qc>October 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Dyskinesia</keyword>
  <keyword>Levodopa-induced Dyskinesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Dyskinesia, Drug-Induced</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

